Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Post by Francine01on Jan 28, 2021 5:39pm
419 Views
Post# 32414677

There is something wrong or fishy

There is something wrong or fishy Is it me, or something is weird with the yesterday, Jan 27 PR ?

It says that August 13, 2020, 82,626,562 common shares were sold with the ATM, but :

1) 82 M "new shares" are not registred neither on the Nasdaq or TSX. As of today, 96,892,000 shares are listed and not 179,495,705 as written in the PR.

2) SP was around 71cents around August 13, and SP drop to 20 cents in september, buyers had 3 weeks to cash significant profit before T2 negatve results, the timing is very strange.  

2) As of August 2020, T2 results were not disclosed, so why management issued shares at 50% discount compared to market value ?  Management was blinded and still disclosing that they were confident with T2 positive results ?  .. did they had material information that was not communicated to the shareholders ? 

3) Why management did not disclosed in August or September that they issued shares 82 M at 34 cents ? Was it for friends and family ? Why that discount ? 

4) Since September, Management is silent ? what is going on? they have in hands all seconday end points, is it because they need time for the 82 M shares to be liquidate on the market before releasing negative informations .. 

5) The CFO JF Boily left in september, did he left because he was not comfortable with this ? 

I think SEC and AMF should investigate was is going with Jan and Pierre, something is very fishy unless the PR is incorrect ... 
<< Previous
Bullboard Posts
Next >>